СoviVac developer announced 2-fold increase in production capacity

The Chumakov Center announced the completion of the equipment modernization, which will increase the production capacity of the COVID-19 СoviVac vaccine by 2-2.5 times. Izvestia reports this regarding the statement of the head of the M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Preparations RAS Aydar Ishmukhametov.

“We have already started vaccine production using new equipment. It will allow the center to increase its capacity by 2–2.5 times. Therefore, we believe that shortly, СoviVac will become much more accessible to all Russian citizens, ” Aydar Ishmukhametov said.

At the moment, 1.5 million doses have been released into civilian circulation. However, by increasing the production capacity by the end of the year, the developer plans to increase their number to 2.5 million doses.

In August, Ishmukhametov announced that СoviVac was being modified to accommodate new strains of COVID-19, including the Delta strain. It is assumed that the updated version of the vaccine may contain two doses at once.

On August 20, it became known that the Chumakov Center is negotiating with foreign partners to approve the use of СoviVac in the countries of Southeast Asia, as well as Central and South America. On the same day, it was reported that the producers of СoviVac had applied for its approval in South Korea.

As the Bashinform News Agency previously reported, the release of the СoviVac vaccine, which is in great demand among Russians, was suspended for several months, and the developer of the drug, the Chumakov Center, closed the site for modernization where raw materials for the COVID-19 vaccine are produced.